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Abstract: A case of cytomegalovirus (CMV) retinitis in a patient with Wegener’s granulomatosis 
treated with oral valganciclovir as maintenance therapy is reported. A 68-year-old male patient 
with anti-proteinase-3 ANCA-positive Wegener’s granulomatosis who was receiving immuno-
suppressive therapy with methylprednisolone, cyclophosphamide, and azathioprine developed 
CMV retinitis. The patient received intravenous ganciclovir as induction therapy and oral valgan-
ciclovir as maintenance therapy. The patient responded to treatment and showed no recurrence 
for 8 months. There were no serious adverse effects associated with oral   valganciclovir. Oral 
valganciclovir is convenient and effective for the management of CMV retinitis in the patient 
with Wegener’s granulomatosis.
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Introduction
Cytomegalovirus (CMV) retinitis is an opportunistic infection in patients with acquired 
immunodeficiency syndrome who are receiving immunosuppressive therapy, which 
causes progressive retinal destruction or retinal detachment with severe visual impair-
ment, and affects quality of life.1–3 The primary treatment for CMV retinitis is intra-
venous ganciclovir. In recent years, oral valganciclovir has been reported as being as 
effective as intravenous ganciclovir and is convenient for the long-term management 
of CMV retinitis in patients with acquired immunodeficiency syndrome.3
CMV retinitis in patients with Wegener’s granulomatosis is rare.4 Therefore, 
therapeutic reporting on CMV retinitis in Wegener’s granulomatosis is inadequate.5–7 
To our knowledge, there have been no previous reports on oral valganciclovir therapy 
for CMV retinitis in Wegener’s granulomatosis.
We report a case of CMV retinitis in a patient with Wegener’s granulomatosis 
treated with intravenous ganciclovir as induction therapy and oral valganciclovir as 
maintenance therapy.
Case report
A 68-year-old man presented to the Department of Ophthalmology, Jikei University 
of Medicine, Katushika Medical Center complaining of vision loss in his right eye for 
the previous month. The patient had been diagnosed with anti-proteinase-3 ANCA-
positive Wegener’s granulomatosis eight years previously, and was receiving immu-
nosuppressive therapy with methylprednisolone, cyclophosphamide, and azathioprine. 
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He developed glomerulonephritis, rhinitis, pulmonary 
nodules as coin lesions, and nodules on the elbow. His 
right vision was finger counting 1 per meter and left vision 
was 20/20. There were grade 2+ cells in his right anterior 
chamber. His left anterior chamber was normal. On fundus 
examination, the right eye showed yellowish-white retinitis 
surrounding the inferior and temporal aspect of the macula 
and along the superior vascular arcades as typical changes 
of CMV retinitis, angiostenosis of the inferior vascular 
arcades, and retinal hemorrhage   (Figure 1). Retinal hemor-
rhage was observed around the inferior and temporal aspect 
of the macula in the left eye. Polymerase chain reaction 
of the aqueous sample was positive for CMV retinitis and 
negative for herpes simplex virus, herpes zoster virus, and 
toxoplasmosis. From these clinical findings, the laboratory 
results, and treatment with immunosuppressive therapy, we 
diagnosed CMV retinitis.
After providing informed consent, the patient received 
intravenous ganciclovir 5 mg/kg twice a day for 25 days as 
induction therapy with monitoring of retinitis, followed by 
oral valganciclovir 900 mg once a day as maintenance therapy. 
At 1 month from onset, there was no further progression of 
retinitis. Three months afterwards, development of retinal 
pigment epithelial changes and reduction of retinal hemor-
rhage were observed in the right eye (Figure 2). Reduction 
of retinal hemorrhage was also observed in the left eye. Oral 
valganciclovir therapy was continued because of continuation 
of immunosuppressive therapy. Transient diarrhea developed 
as an adverse effect associated with valganciclovir. There was 
no recurrence of retinitis after 8 months, but visual acuity was 
not improved.
Discussion
Valganciclovir is an orally administered prodrug that is rap-
idly hydrolyzed to ganciclovir, the active compound.8,9 The 
absolute bioavailability of ganciclovir from valganciclovir is 
60%,10 and a dose of 900 mg results in ganciclovir blood levels 
similar to those obtained using an intravenous ganciclovir 
dose of 5 mg/kg body weight.11 Adverse effects associated 
with valganciclovir include pancytopenia, nausea, vomiting, 
diarrhea, peripheral neuropathy, seizures, and confusion.9 
This patient developed only transient diarrhea. Pancytopenia 
was not present on the basis of blood test results.
Maintenance therapy is needed for patients receiving 
immunosuppressive therapy. Previously, the only treatment 
for cytomegalovirus retinitis was via the intravenous route, 
so patients are at risk of catheter-related complications.1 
Oral valganciclovir can reduce the risk of catheter-related 
complications in particular infections, which is beneficial 
for patients with Wegener’s granulomatosis.3
Wegener’s granulomatosis causes a variety of ophthalmic 
symptoms,12 but the development of CMV retinitis is 
rare.4 According to previous reports of CMV retinitis in 
Wegener’s granulomatosis, intravenous ganciclovir and 
intravitreal implant treatment have been described.5–7 
The ganciclovir implant is more effective than intrave-
nous ganciclovir, but patients treated with a ganciclovir 
implant alone remain at greater risk for the development 
of cytomegalovirus disease outside of the treated eye.2 
Figure 1 The right eye showed yellowish-white retinitis surrounding the inferior and 
temporal aspect of the macula and along the superior vascular arcades, angiostenosis 
of the inferior vascular arcades, and retinal hemorrhage.
Figure 2 After treatment, development of retinal pigment epithelial changes and 
reduction of retinal hemorrhage were observed in the right eye.
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Therefore, a ganciclovir implant is administered; it is 
done in combination with intravenous ganciclovir or oral 
valganciclovir.8 There are risks of complications associated 
with implant insertion,2,13 so ganciclovir implant adaptation 
should be carefully considered.
In this patient, we selected intravenous ganciclovir as 
the initial treatment given the involvement of both eyes, 
the severity of CMV retinitis, and his general condition, 
followed by oral valganciclovir as maintenance treatment, 
and achieved a remission. From this time forward, we will 
consider alternative treatments, ie, a ganciclovir intravitreal 
implant, intravenous foscarnet, and intravenous cidofovir,8 
according to the patient’s condition.
Conclusion
We report a case of CMV retinitis in a patient with Wegener’s 
granulomatosis treated with intravenous ganciclovir as 
induction therapy and oral valganciclovir as maintenance 
therapy. There were no serious adverse effects associated 
with oral valganciclovir, which was convenient and effec-
tive for the management of CMV retinitis in a patient 
with Wegener’s granulomatosis. In the future, use of oral 
valganciclovir for the treatment of CMV retinitis in Wegener’s 
granulomatosis is likely to increase.
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